Cargando…

RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor

Although treatment with imatinib, which inhibits KIT and PDGFR, controls advanced disease in about 80% of gastrointestinal stromal tumor (GIST) patients, resistance to imatinib often develops. RACK1 (Receptor for Activated C Kinase 1) is a ribosomal protein that contributes to tumor progression by a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Xiaodong, Xue, Anwei, Fang, Yong, Shu, Ping, Ling, Jiaqian, Hou, Yingyong, Shen, Kuntang, Qin, Jing, Sun, Yihong, Qin, Xinyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924716/ https://www.ncbi.nlm.nih.gov/pubmed/26893362 http://dx.doi.org/10.18632/oncotarget.7426

Ejemplares similares

Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib
por: Gao, Xiaodong, et al.
Publicado: (2016)

Clinical and Prognostic Significance of Tumor-Infiltrating CD8+ T Cells and PD-L1 Expression in Primary Gastrointestinal Stromal Tumors
por: Sun, Xiangfei, et al.
Publicado: (2021)

Role of Surgery in the Management of Liver Metastases From Gastrointestinal Stromal Tumors
por: Xue, Anwei, et al.
Publicado: (2022)

Comparison of prognostic prediction models for rectal gastrointestinal stromal tumor
por: Jiaxin, Liu, et al.
Publicado: (2020)

Gastrointestinal stromal tumors (GISTs) with remarkable cystic change: a specific subtype of GISTs with relatively indolent behaviors and favorable prognoses
por: Xue, Anwei, et al.
Publicado: (2019)

THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours
por: Sun, Jianyi, et al.
Publicado: (2022)

Overexpression of RACK1 Predicts Poor Prognosis in Melanoma
por: Shen, Congcong, et al.
Publicado: (2020)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment
por: Yin, Yuan, et al.
Publicado: (2016)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013)

Update on imatinib for gastrointestinal stromal tumors: duration of treatment
por: Linch, Mark, et al.
Publicado: (2013)

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

GSTT1 Copy Number Gain and ZNF Overexpression Are Predictors of Poor Response to Imatinib in Gastrointestinal Stromal Tumors
por: Lee, Eui Jin, et al.
Publicado: (2013)

Chloroquine Combined with Imatinib Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumors by Inhibiting Autophagy via the MAPK/ERK Pathway
por: Zheng, Song, et al.
Publicado: (2020)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib
por: Lei, Tianxiang, et al.
Publicado: (2021)

Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experience
por: Azribi, F, et al.
Publicado: (2009)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
por: Sicklick, Jason K., et al.
Publicado: (2013)

Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib
por: Moryoussef, Frédérick, et al.
Publicado: (2015)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors
por: Takahashi, Tsuyoshi, et al.
Publicado: (2017)

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Gastrointestinal Stromal Tumor With Chondrosarcomatous Dedifferentiation Following Imatinib Therapy
por: Koufopoulos, Nektarios, et al.
Publicado: (2021)

Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor
por: Wang, Gang, et al.
Publicado: (2021)

Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors
por: Cao, Lei, et al.
Publicado: (2022)

A narrative review of imatinib-resistant gastrointestinal stromal tumors
por: Hayashi, Yujiro, et al.
Publicado: (2021)

Inhibition of stromal‐interacting molecule 1‐mediated store‐operated Ca(2+) entry as a novel strategy for the treatment of acquired imatinib‐resistant gastrointestinal stromal tumors
por: Yang, Ziyi, et al.
Publicado: (2018)

Upregulation of ZNF148 in SDHB‐deficient gastrointestinal stromal tumor potentiates Forkhead box M1‐mediated transcription and promotes tumor cell invasion
por: Gao, Xiaodong, et al.
Publicado: (2020)

Prolonging Gastrointestinal-Stromal-Tumor-free life, an optimal suggestion of imatinib intervention ahead of operation
por: Yan, Lin-Hai, et al.
Publicado: (2018)

AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis
por: Li, Chien-Feng, et al.
Publicado: (2014)

Expression of stem cell factor in gastrointestinal stromal tumors: Implications for proliferation and imatinib resistance
por: HOU, XIAO-WEI, et al.
Publicado: (2013)

Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
por: Date, Ravindra S, et al.
Publicado: (2008)

Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
por: Annaberdyev, Shohrat, et al.
Publicado: (2009)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor
por: Quezada, Nicolás, et al.
Publicado: (2014)

Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib
por: Jiang, Xiaoyin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fdhjtfco44gknnsjktsf1e9doo